PF-06250112 |
| Catalog No.GC34709 |
PF-06250112 es un inhibidor de BTK potente, altamente selectivo y biodisponible por vÍa oral con una IC50 de 0,5 nM, muestra un efecto inhibitorio hacia la tirosina quinasa no receptora BMX y TEC con IC50 de 0,9 nM y 1,2 nM, respectivamente.
Products are for research use only. Not for human use. We do not sell to patients.
Cas No.: 1609465-89-5
Sample solution is provided at 25 µL, 10mM.
;)
,-1-7$$$37316672.jpg');)
;)
;)
$$$36806353.jpg');)
;33(7)%EF%BC%9A546-561$$$37156877.jpg');)
;)
;)
;)
%201124-1138.$$$35908550.jpg');)
%20766-780.$$$37100057.jpg');)
%20418-432.$$$36893736.jpg');)
%EF%BC%9A-240-255.$$$35108512.jpg');)
533-545$$$36543525.jpg');)
%201-13.$$$36600053.jpg');)
;)
PF-06250112 is a potent, highly selective, orally bioavailable BTK inhibitor with an IC50 of 0.5 nM, shows inhibitory effect toward BMX nonreceptor tyrosine kinase and TEC with IC50s of 0.9 nM and 1.2 nM, respectively[1]. IC50: 0.5 nM (BTK), 0.9 nM (BMX), 1.2 nM (TEC)[1]
[1]. Rankin AL, et al. Selective inhibition of BTK prevents murine lupus and antibody-mediated glomerulonephritis. J Immunol. 2013 Nov 1;191(9):4540-50.
Average Rating: 5 (Based on Reviews and 1 reference(s) in Google Scholar.)
GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.
Required fields are marked with *